None listed
Conditions
Brief summary
This study will investigate the safety and tolerability of sodium selenate in patients with behavioural variant frontotemporal dementia. All participants will be given sodium selenate for 52 weeks, and assessed regularly to investigate any negative reactions to the drug, as well as any positive effects on the symptoms of their dementia, as measured by biological samples, cognitive tests and brain scans.
Interventions
Each participant will receive capsules of sodium selenate 15mg three times a day (which may be reduced to 10mg three times a day) for 52 weeks. A dose reduction will be made in the event of intolerable adverse events experienced by the participant at their next scheduled or unscheduled visit as decided by on the the study doctors.
Participants/partners will be required to bring unused medications to each visit to measure compliance, as well as recording any missed doses in their study diary.
Sponsors
Melbourne Health
Study design
Allocation
Non-randomised trial
Intervention model
Single group
Primary purpose
Treatment
Masking
Open (masking not used)
Eligibility
Sex/Gender
All
Age
35 Years to No maximum
Healthy volunteers
No
Inclusion criteria
Diagnosis of possible behavioural variant FTD MRI not inconsistent with FTD Responsible caregiver who can ensure participants compliance with study procedures and dosing of drug
Exclusion criteria
Contra-indication to lumbar puncture Positive amyloid PET scan Known family history of Alzheimer's Disease Significant uncontrolled medical condition Known sensitivity to sodium selenate or related compounds
Outcome results
None listed